Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.
This study explores the effects of 3'-deoxyadenosine, a compound from Cordyceps militaris, on lipid metabolic disorder induced by a high-fat-diet in C57BL/6 mice. These mice had an obese body, lipid metabolic disorder and insulin resistance and were treated orally with 100 mg/kg/day 3'-deoxyadenosine (DA), 15 mg/kg/day rosiglitazone and 150 mg/kg/day fenofibrate, respectively. Compared to the model mice, the body weight gain in DA-treated mice were decreased by 66.5%, serum triglyceride and total cholesterol levels were decreased by 20.7% and 16.7%, respectively, and the triglyceride content in the skeletal muscle was reduced by 41.2%. This treatment also had a significant effect on insulin resistance. In DA-treated mice, the serum insulin levels and homeostasis model assessment of the insulin resistance index were decreased by 30% and 46%, respectively, and the areas under the glucose-time curve were depressed by 18% in the insulin tolerance test and by 21.5% in the oral glucose tolerance test. Finally, the value of glucose infusion rates and insulin induced-glucose uptake into the skeletal muscle in the hyperinsulinemic-euglycemic clamp test were increased by 18% and 41%, respectively, compared to those in the model mice. This data suggests that the effects of DA on lipid metabolic disorder induced by a high-fat-diet may be linked to its improvement on insulin resistance, especially concerning the increase of insulin sensitivity in the skeletal muscle.
Institute of Materia Medica, Chinese Academy of Medical Sciences, Perking Union Medical College, Beijing, China.
Ya-Jing
YJ
Niu
Rong-Ya
RY
Tao
Qian
Q
Liu
Jin-Ying
JY
Tian
Fei
F
Ye
Ping
P
Zhu
Hai-Bo
HB
Zhu
D000818:Animals; D019540:Area Under Curve; D032661:Cordyceps / Q000737:chemistry*; D003839:Deoxyadenosines / Q000494:pharmacology / Q000627:therapeutic use*; D004041:Dietary Fats / Q000009:adverse effects* / Q000378:metabolism; D004195:Disease Models, Animal; D011345:Fenofibrate / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D015309:Glucose Clamp Technique; D018149:Glucose Intolerance / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D050356:Lipid Metabolism / Q000187:drug effects*; D052439:Lipid Metabolism Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008517:Phytotherapy; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D015430:Weight Gain / Q000187:drug effects
D003839:Deoxyadenosines; D004041:Dietary Fats; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005947:Glucose; D011345:Fenofibrate